{"editorial":{"content_id":"92d38b7f-cbc6-4b91-a129-6733e201fbfd","slug":"interfarma-20261019-43b3be","content_type":"news","title":"Interfarma批准更新行为准则第7、11节及问答文件","summary":"巴西制药行业协会Interfarma董事会10月初批准《行为准则》第7节（活动）和第11节（传播行动）的更新及问答文件修订，以强化行业自律。","body":"巴西制药行业协会Interfarma董事会于10月初批准了《行为准则》第7节（活动）和第11节（传播行动）的更新，以及《问答文件》（Q&As）的修订。该工作由Interfarma合规委员会完成，旨在为现有条款提供更大的清晰度和解释安全性。\n\n据Interfarma介绍，此次更新属于有针对性的现代化调整，并非对《行为准则》的全面修订，目的是保留准则的指导原则并加强其在会员企业中的实际应用。更新依据包括行业实践的演变、对国际参考的观察以及多年来准则应用积累的经验。\n\n第7节针对活动，强化了活动科学和教育目的、相称性、专业性及举办地点适宜性等方面的标准，并明确纳入面向公众的健康意识行动，同时须遵守准则原则和适用法律。\n\n第11节重点更新数字环境和传播行动相关指南，巩固透明度、编辑责任、信息完整性、监管合规及第三方关系治理等原则，并对涉及社交媒体、数字平台、影响者和内容创作者的情形作出更清晰的说明。\n\n《问答文件》也得到改进，以增强其指导作用，为会员企业提供更大的解释安全性，并促进准则条款的统一适用。Interfarma表示，此次批准重申其对持续改进自律工具以及推动制药行业在对外关系中保持高道德、诚信、透明和责任标准的承诺。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["合规","行业趋势","br-health"],"content_level":"编辑整理","event_type":"行业自律","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-10-19T11:03:00.606Z","display_date":"2026-10-19","source_published_at":null,"source_url":"https://www.interfarma.org.br/interfarma-fortalece-autorregulacao-com-atualizacao-do-codigo-de-conduta-e-de-qas/","source_name":"Interfarma","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":["compliance_risk","regulatory_uncertainty"],"opportunity_flags":[],"trend_signals":["policy_tightening"]},"intelligence":{"intel_id":"a62e31f7-5afe-4510-b414-7633f4c16c84","version":1,"event_type":"政策发布","event_date":null,"main_entities":[{"name":"Interfarma","role":"巴西制药行业协会，董事会批准《行为准则》更新及问答文件修订","type":"sector","country":"巴西","normalized_name":null},{"name":"Interfarma合规委员会","role":"完成《行为准则》第7节、第11节及《问答文件》修订工作","type":"sector","country":"巴西","normalized_name":null},{"name":"《行为准则》第7节和第11节及《问答文件》","role":"被批准更新的行业自律文件，涉及活动及传播行动","type":"policy","country":"巴西","normalized_name":null}],"main_action":"Interfarma董事会批准行为准则第7、11节及问答文件修订。","key_numbers":[],"facts":[{"verified":false,"statement":"Interfarma董事会于10月初批准《行为准则》第7节（活动）和第11节（传播行动）的更新，以及《问答文件》的修订。","source_excerpt":null},{"verified":false,"statement":"该更新工作由Interfarma合规委员会完成，旨在为现有条款提供更大的清晰度和解释安全性。","source_excerpt":null},{"verified":false,"statement":"第7节强化活动科学和教育目的、相称性、专业性及举办地点适宜性等标准，并明确纳入面向公众的健康意识行动。","source_excerpt":null},{"verified":false,"statement":"第11节更新数字环境和传播行动相关指南，并对涉及社交媒体、数字平台、影响者和内容创作者的情形作出更清晰说明。","source_excerpt":null}],"assessments":[{"statement":"此次更新属于针对性现代化调整而非全面修订，主要目的是提升条款解释安全性和会员企业统一适用性。","confidence":"high","basis_fact_index":null},{"statement":"第11节更新可能提高制药企业在社交媒体、数字平台及影响者合作方面的合规要求与执行成本。","confidence":"medium","basis_fact_index":null},{"statement":"该批准体现巴西制药行业自律工具持续收紧，但对非会员企业不必然具有直接法律约束力。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"跟进Interfarma正式发布的更新文本、生效日期及适用过渡安排。"},{"target":"user","priority":"high","description":"评估第11节更新对社交媒体、数字平台、影响者和内容创作者合作合规流程的影响。"},{"target":"user","priority":"normal","description":"建议会员企业及合规团队对照第7节更新审查活动目的、地点适宜性和公众健康意识行动安排。"}],"affected_audience":["Interfarma会员制药企业","制药企业合规部门","市场传播与数字营销团队","活动组织者","与制药企业合作的影响者和内容创作者"],"risk_flags":["compliance_risk","regulatory_uncertainty"],"opportunity_flags":[],"trend_signals":["policy_tightening"],"follow_up_needed":true,"follow_up_questions":["更新后的《行为准则》正式文本和生效日期是什么？","第11节对社交媒体、数字平台、影响者和内容创作者的具体合规要求有哪些？","该更新是否适用于非Interfarma会员企业或仅作为行业自律参考？","Interfarma是否将发布实施指引、培训或过渡期安排？"],"related_topics":["巴西制药行业","行业自律","Interfarma","行为准则","数字传播合规","影响者营销","活动合规"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-19T11:03:12.689Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/interfarma-20261019-43b3be","api_url":"https://chinabrazilinsight.com/api/public/content/interfarma-20261019-43b3be","markdown_url":"https://chinabrazilinsight.com/api/public/content/interfarma-20261019-43b3be?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/interfarma-20261019-43b3be?view=json","last_updated":"2026-10-19T11:03:12.992Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}